Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|September 10, 2021
MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical ModelsKai-Wen Huang, Choon Ping Tan, Vikash Reebye, et al.
Neoplasia (New York, N.Y.)|June 22, 2005
Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imagingSimon P Robinson, Tammy L Kalber, Franklyn A Howe, et al.
Molecular Cancer Therapeutics|March 11, 2011
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand bindingJane Kendrew, Cath Eberlein, Brad Hedberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126Jeffrey L Evelhoch, Patricia M LoRusso, Zhanquan He, et al.
Cancer Research|January 20, 2011
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growthJin Gao, Jon W Chesebrough, Susan A Cartlidge, et al.
Cancer Research|December 25, 2002
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculaturePeter D Davis, Graeme J Dougherty, David C Blakey, et al.
Molecular Cancer Therapeutics|January 8, 2010
A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical modelsJeffrey L Brown, Z Alexander Cao, Maria Pinzon-Ortiz, et al.
Oncogene|March 8, 2018
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancerVikash Reebye, Kai-Wen Huang, Vivian Lin, et al.
Science Translational Medicine|June 16, 2017
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRASSarah J Ross, Alexey S Revenko, Lyndsey L Hanson, et al.
Molecular Cancer Therapeutics|June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivoDavid W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Pageof 3